-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $12.5

Benzinga·08/14/2026 11:21:18
Listen to the news
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.